{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T17:54:02Z","timestamp":1790704442471,"version":"4.1.0"},"reference-count":122,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100013945","name":"Institut de Recherches Servier","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013945","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003100","name":"F\u00e9d\u00e9ration Fran\u00e7aise de Cardiologie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003100","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Archives of Cardiovascular Diseases"],"published-print":{"date-parts":[[2020,12]]},"DOI":"10.1016\/j.acvd.2020.09.002","type":"journal-article","created":{"date-parts":[[2020,10,23]],"date-time":"2020-10-23T02:23:53Z","timestamp":1603419833000},"page":"797-810","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["Severe acute respiratory syndrome coronavirus 2 and renin-angiotensin system blockers: A review and pooled analysis"],"prefix":"10.1016","volume":"113","author":[{"given":"Mathieu","family":"Kerneis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5949-0855","authenticated-orcid":false,"given":"Arnaud","family":"Ferrante","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Guedeney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Vicaut","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gilles","family":"Montalescot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.acvd.2020.09.002_bib0615","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/S0140-6736(20)30183-5","article-title":"Clinical features of patients infected with 2019 novel coronavirus in Wuhan","volume":"395","author":"Huang","year":"2020","journal-title":"China. Lancet"},{"key":"10.1016\/j.acvd.2020.09.002_bib0620","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1038\/s41586-020-2012-7","article-title":"A pneumonia outbreak associated with a new coronavirus of probable bat origin","volume":"579","author":"Zhou","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.acvd.2020.09.002_bib0625","doi-asserted-by":"crossref","first-page":"e21","DOI":"10.1016\/S2213-2600(20)30116-8","article-title":"Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection?","volume":"8","author":"Fang","year":"2020","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.acvd.2020.09.002_bib0630","doi-asserted-by":"crossref","first-page":"1708","DOI":"10.1056\/NEJMoa2002032","article-title":"Clinical Characteristics of Coronavirus Disease 2019 in China","volume":"382","author":"Guan","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.acvd.2020.09.002_bib0635","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1007\/s00392-020-01626-9","article-title":"Prevalence and impact of cardiovascular metabolic diseases on COVID-19 in China","volume":"109","author":"Li","year":"2020","journal-title":"Clin Res Cardiol"},{"key":"10.1016\/j.acvd.2020.09.002_bib0640","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1038\/s41569-020-0360-5","article-title":"COVID-19 and the cardiovascular system","volume":"17","author":"Zheng","year":"2020","journal-title":"Nat Rev Cardiol"},{"key":"10.1016\/j.acvd.2020.09.002_bib0645","first-page":"1054","article-title":"Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan","volume":"395","author":"Zhou","year":"2020","journal-title":"China: a retrospective cohort study. Lancet"},{"key":"10.1016\/j.acvd.2020.09.002_bib0650","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/S2213-2600(20)30079-5","article-title":"Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study","volume":"8","author":"Yang","year":"2020","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.acvd.2020.09.002_bib0655","doi-asserted-by":"crossref","first-page":"2549","DOI":"10.1016\/S0140-6736(17)32478-9","article-title":"Prevalence, awareness, treatment, and control of hypertension in China: data from 1.7 million adults in a population-based screening study (China PEACE Million Persons Project)","volume":"390","author":"Lu","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.acvd.2020.09.002_bib0660","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1536\/ihj.50.501","article-title":"Effects of ARB or ACE-inhibitor administration on plasma levels of aldosterone and adiponectin in hypertension","volume":"50","author":"Nakamura","year":"2009","journal-title":"Int Heart J"},{"key":"10.1016\/j.acvd.2020.09.002_bib0665","doi-asserted-by":"crossref","first-page":"2605","DOI":"10.1161\/CIRCULATIONAHA.104.510461","article-title":"Effect of angiotensin-converting enzyme inhibition and angiotensin II receptor blockers on cardiac angiotensin-converting enzyme 2","volume":"111","author":"Ferrario","year":"2005","journal-title":"Circulation"},{"key":"10.1016\/j.acvd.2020.09.002_bib0670","doi-asserted-by":"crossref","DOI":"10.1016\/j.cell.2020.02.052","article-title":"SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor","volume":"181","author":"Hoffmann","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.acvd.2020.09.002_bib0675","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/S0140-6736(20)30251-8","article-title":"Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding","volume":"395","author":"Lu","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.acvd.2020.09.002_bib0680","first-page":"94","article-title":"Receptor Recognition by the Novel Coronavirus from Wuhan: an Analysis Based on Decade-Long Structural Studies of SARS Coronavirus","author":"Wan","year":"2020","journal-title":"J Virol"},{"key":"10.1016\/j.acvd.2020.09.002_bib0685","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1126\/science.abb2762","article-title":"Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2","volume":"367","author":"Yan","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.acvd.2020.09.002_bib0690","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1002\/ddr.21656","article-title":"Angiotensin receptor blockers as tentative SARS-CoV-2 therapeutics","volume":"81","author":"Gurwitz","year":"2020","journal-title":"Drug Dev Res"},{"key":"10.1016\/j.acvd.2020.09.002_bib0695","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1038\/nature03712","article-title":"Angiotensin-converting enzyme 2 protects from severe acute lung failure","volume":"436","author":"Imai","year":"2005","journal-title":"Nature"},{"key":"10.1016\/j.acvd.2020.09.002_bib0700","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1038\/nm1267","article-title":"A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus-induced lung injury","volume":"11","author":"Kuba","year":"2005","journal-title":"Nat Med"},{"key":"10.1016\/j.acvd.2020.09.002_bib0705","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1007\/s00134-020-05985-9","article-title":"Angiotensin-converting enzyme 2 (ACE2) as a SARS-CoV-2 receptor: molecular mechanisms and potential therapeutic target","volume":"46","author":"Zhang","year":"2020","journal-title":"Intensive Care Med"},{"key":"10.1016\/j.acvd.2020.09.002_bib0710","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.cardfail.2020.04.013","article-title":"Statement Addresses Concerns Re: Using RAAS Antagonists in COVID-19","volume":"26","author":"HFSA\/ACC\/AHA","year":"2020","journal-title":"J Card Fail"},{"key":"10.1016\/j.acvd.2020.09.002_bib0715","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1002\/ejhf.1924","article-title":"Angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers are not associated with severe COVID-19 infection in a multi-site UK acute hospital trust","volume":"22","author":"Bean","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.acvd.2020.09.002_bib0720","doi-asserted-by":"crossref","first-page":"e10","DOI":"10.1161\/HYPERTENSIONAHA.120.15312","article-title":"Renin-Angiotensin-Aldosterone System Inhibitors and Outcome in Patients With SARS-CoV-2 Pneumonia. A Case Series Study","volume":"76","author":"Conversano","year":"2020","journal-title":"Hypertension"},{"key":"10.1016\/j.acvd.2020.09.002_bib0725","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1001\/jamacardio.2020.1624","article-title":"Association of Renin-Angiotensin System Inhibitors With Severity or Risk of Death in Patients With Hypertension Hospitalized for Coronavirus Disease 2019 (COVID-19) Infection in Wuhan, China","volume":"5","author":"Li","year":"2020","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.acvd.2020.09.002_bib0730","doi-asserted-by":"crossref","first-page":"2431","DOI":"10.1056\/NEJMoa2006923","article-title":"Renin-Angiotensin-Aldosterone System Blockers and the Risk of Covid-19","volume":"382","author":"Mancia","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.acvd.2020.09.002_bib0735","doi-asserted-by":"crossref","DOI":"10.1001\/jamacardio.2020.1855","article-title":"Association of Use of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers With Testing Positive for Coronavirus Disease 2019 (COVID-19)","author":"Mehta","year":"2020","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.acvd.2020.09.002_bib0740","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1080\/22221751.2020.1746200","article-title":"Renin-angiotensin system inhibitors improve the clinical outcomes of COVID-19 patients with hypertension","volume":"9","author":"Meng","year":"2020","journal-title":"Emerg Microbes Infect"},{"key":"10.1016\/j.acvd.2020.09.002_bib0745","doi-asserted-by":"crossref","first-page":"2441","DOI":"10.1056\/NEJMoa2008975","article-title":"Renin-Angiotensin-Aldosterone System Inhibitors and Risk of Covid-19","volume":"382","author":"Reynolds","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.acvd.2020.09.002_bib0750","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1161\/HYPERTENSIONAHA.120.15143","article-title":"Effects of Angiotensin II Receptor Blockers and ACE (Angiotensin-Converting Enzyme) Inhibitors on Virus Infection, Inflammatory Status, and Clinical Outcomes in Patients With COVID-19 and Hypertension: A Single-Center Retrospective Study","volume":"76","author":"Yang","year":"2020","journal-title":"Hypertension"},{"key":"10.1016\/j.acvd.2020.09.002_bib0755","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1161\/CIRCRESAHA.120.317134","article-title":"Association of Inpatient Use of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers With Mortality Among Patients With Hypertension Hospitalized With COVID-19","volume":"126","author":"Zhang","year":"2020","journal-title":"Circ Res"},{"key":"10.1016\/j.acvd.2020.09.002_bib0760","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1080\/10641963.2020.1764018","article-title":"Clinical characteristics of coronavirus disease 2019 (COVID-19) patients with hypertension on renin-angiotensin system inhibitors","volume":"42","author":"Zhou","year":"2020","journal-title":"Clin Exp Hypertens"},{"key":"10.1016\/j.acvd.2020.09.002_bib0765","first-page":"14","article-title":"An Update on the Tissue Renin Angiotensin System and Its Role in Physiology and Pathology","volume":"6","author":"Nehme","year":"2019","journal-title":"J Cardiovasc Dev Dis"},{"key":"10.1016\/j.acvd.2020.09.002_bib0770","doi-asserted-by":"crossref","first-page":"H958","DOI":"10.1152\/ajpheart.00723.2018","article-title":"The renin-angiotensin system: going beyond the classical paradigms","volume":"316","author":"Santos","year":"2019","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"10.1016\/j.acvd.2020.09.002_bib0775","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1161\/01.HYP.32.3.387","article-title":"Pathways for angiotensin II generation in intact human tissue: evidence from comparative pharmacological interruption of the renin system","volume":"32","author":"Hollenberg","year":"1998","journal-title":"Hypertension"},{"key":"10.1016\/j.acvd.2020.09.002_bib0780","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1023\/A:1002848402911","article-title":"Angiotensin II-generating enzymes","volume":"65","author":"Belova","year":"2000","journal-title":"Biochemistry (Mosc)"},{"key":"10.1016\/j.acvd.2020.09.002_bib0785","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1097\/00004872-198912000-00001","article-title":"Multiple pathways of angiotensin production in the blood vessel wall: evidence, possibilities and hypotheses","volume":"7","author":"Dzau","year":"1989","journal-title":"J Hypertens"},{"issue":"Suppl 3","key":"10.1016\/j.acvd.2020.09.002_bib0790","doi-asserted-by":"crossref","first-page":"S34","DOI":"10.1038\/sj.jhh.1001437","article-title":"The potential role of AT(1)-receptor blockade in the prevention and reversal of atherosclerosis","volume":"16","author":"Papademetriou","year":"2002","journal-title":"J Hum Hypertens"},{"key":"10.1016\/j.acvd.2020.09.002_bib0795","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1097\/FJC.0000000000000208","article-title":"AT2 receptor activities and pathophysiological implications","volume":"65","author":"Matavelli","year":"2015","journal-title":"J Cardiovasc Pharmacol"},{"key":"10.1016\/j.acvd.2020.09.002_bib0800","doi-asserted-by":"crossref","first-page":"E1","DOI":"10.1161\/01.RES.87.5.e1","article-title":"A novel angiotensin-converting enzyme-related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1-9","volume":"87","author":"Donoghue","year":"2000","journal-title":"Circ Res"},{"key":"10.1016\/j.acvd.2020.09.002_bib0805","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/S0014-5793(02)03640-2","article-title":"Quantitative mRNA expression profiling of ACE 2, a novel homologue of angiotensin converting enzyme","volume":"532","author":"Harmer","year":"2002","journal-title":"FEBS Lett"},{"key":"10.1016\/j.acvd.2020.09.002_bib0810","doi-asserted-by":"crossref","first-page":"33238","DOI":"10.1074\/jbc.M002615200","article-title":"A human homolog of angiotensin-converting enzyme. Cloning and functional expression as a captopril-insensitive carboxypeptidase","volume":"275","author":"Tipnis","year":"2000","journal-title":"J Biol Chem"},{"key":"10.1016\/j.acvd.2020.09.002_bib0815","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1007\/s11684-020-0754-0","article-title":"Single-cell RNA-seq data analysis on the receptor ACE2 expression reveals the potential risk of different human organs vulnerable to 2019-nCoV infection","volume":"14","author":"Zou","year":"2020","journal-title":"Front Med"},{"key":"10.1016\/j.acvd.2020.09.002_bib0820","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1042\/BJ20040634","article-title":"Evaluation of angiotensin-converting enzyme (ACE), its homologue ACE2 and neprilysin in angiotensin peptide metabolism","volume":"383","author":"Rice","year":"2004","journal-title":"Biochem J"},{"key":"10.1016\/j.acvd.2020.09.002_bib0825","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1161\/CIRCRESAHA.110.219279","article-title":"Genetic Ace2 deficiency accentuates vascular inflammation and atherosclerosis in the ApoE knockout mouse","volume":"107","author":"Thomas","year":"2010","journal-title":"Circ Res"},{"key":"10.1016\/j.acvd.2020.09.002_bib0830","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.2337\/db07-1212","article-title":"ACE2 deficiency modifies renoprotection afforded by ACE inhibition in experimental diabetes","volume":"57","author":"Tikellis","year":"2008","journal-title":"Diabetes"},{"key":"10.1016\/j.acvd.2020.09.002_bib0835","doi-asserted-by":"crossref","first-page":"256294","DOI":"10.1155\/2012\/256294","article-title":"Angiotensin-Converting Enzyme 2 (ACE2) Is a Key Modulator of the Renin Angiotensin System in Health and Disease","volume":"2012","author":"Tikellis","year":"2012","journal-title":"Int J Pept"},{"key":"10.1016\/j.acvd.2020.09.002_bib0840","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/j.tips.2004.04.001","article-title":"ACE2: from vasopeptidase to SARS virus receptor","volume":"25","author":"Turner","year":"2004","journal-title":"Trends Pharmacol Sci"},{"key":"10.1016\/j.acvd.2020.09.002_bib0845","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.cardiores.2007.04.007","article-title":"Angiotensin II-mediated oxidative stress and inflammation mediate the age-dependent cardiomyopathy in ACE2 null mice","volume":"75","author":"Oudit","year":"2007","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.acvd.2020.09.002_bib0850","doi-asserted-by":"crossref","first-page":"30113","DOI":"10.1074\/jbc.M505111200","article-title":"Tumor necrosis factor-alpha convertase (ADAM17) mediates regulated ectodomain shedding of the severe-acute respiratory syndrome-coronavirus (SARS-CoV) receptor, angiotensin-converting enzyme-2 (ACE2)","volume":"280","author":"Lambert","year":"2005","journal-title":"J Biol Chem"},{"key":"10.1016\/j.acvd.2020.09.002_bib0855","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1161\/CIRCRESAHA.116.310509","article-title":"Clinical Relevance and Role of Neuronal AT1 Receptors in ADAM17-Mediated ACE2 Shedding in Neurogenic Hypertension","volume":"121","author":"Xu","year":"2017","journal-title":"Circ Res"},{"key":"10.1016\/j.acvd.2020.09.002_bib0860","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1038\/nature02145","article-title":"Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus","volume":"426","author":"Li","year":"2003","journal-title":"Nature"},{"key":"10.1016\/j.acvd.2020.09.002_bib0865","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1002\/path.2067","article-title":"Expression of elevated levels of pro-inflammatory cytokines in SARS-CoV-infected ACE2+ cells in SARS patients: relation to the acute lung injury and pathogenesis of SARS","volume":"210","author":"He","year":"2006","journal-title":"J Pathol"},{"key":"10.1016\/j.acvd.2020.09.002_bib0870","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.1093\/cvr\/cvaa097","article-title":"Hypertension, the renin-angiotensin system, and the risk of lower respiratory tract infections and lung injury: implications for COVID-19","volume":"116","author":"Kreutz","year":"2020","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.acvd.2020.09.002_bib0875","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1093\/ajh\/hpu086","article-title":"Urinary angiotensin-converting enzyme 2 in hypertensive patients may be increased by olmesartan, an angiotensin II receptor blocker","volume":"28","author":"Furuhashi","year":"2015","journal-title":"Am J Hypertens"},{"key":"10.1016\/j.acvd.2020.09.002_bib0880","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1038\/s41569-020-0368-x","article-title":"Interaction between RAAS inhibitors and ACE2 in the context of COVID-19","volume":"17","author":"Mourad","year":"2020","journal-title":"Nat Rev Cardiol"},{"key":"10.1016\/j.acvd.2020.09.002_bib0885","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1161\/01.HYP.0000124667.34652.1a","article-title":"Upregulation of angiotensin-converting enzyme 2 after myocardial infarction by blockade of angiotensin II receptors","volume":"43","author":"Ishiyama","year":"2004","journal-title":"Hypertension"},{"key":"10.1016\/j.acvd.2020.09.002_bib0890","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.regpep.2010.09.005","article-title":"Telmisartan attenuates aortic hypertrophy in hypertensive rats by the modulation of ACE2 and profilin-1 expression","volume":"166","author":"Zhong","year":"2011","journal-title":"Regul Pept"},{"key":"10.1016\/j.acvd.2020.09.002_bib0895","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1097\/HJH.0000000000002450","article-title":"Can angiotensin receptor-blocking drugs perhaps be harmful in the COVID-19 pandemic?","volume":"38","author":"Esler","year":"2020","journal-title":"J Hypertens"},{"key":"10.1016\/j.acvd.2020.09.002_bib0900","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1161\/HYPERTENSIONAHA.114.03743","article-title":"Angiotensin II mediates angiotensin converting enzyme type 2 internalization and degradation through an angiotensin II type I receptor-dependent mechanism","volume":"64","author":"Deshotels","year":"2014","journal-title":"Hypertension"},{"key":"10.1016\/j.acvd.2020.09.002_bib0905","doi-asserted-by":"crossref","first-page":"2189","DOI":"10.1111\/j.1523-1755.2005.00675.x","article-title":"Effects of renin-angiotensin system blockade on renal angiotensin-(1-7) forming enzymes and receptors","volume":"68","author":"Ferrario","year":"2005","journal-title":"Kidney Int"},{"key":"10.1016\/j.acvd.2020.09.002_bib0910","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1007\/s00726-014-1889-6","article-title":"Human intestine luminal ACE2 and amino acid transporter expression increased by ACE-inhibitors","volume":"47","author":"Vuille-dit-Bille","year":"2015","journal-title":"Amino Acids"},{"key":"10.1016\/j.acvd.2020.09.002_bib0915","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1159\/000185629","article-title":"Discrepancy between intrarenal messenger RNA and protein expression of ACE and ACE2 in human diabetic nephropathy","volume":"29","author":"Wang","year":"2009","journal-title":"Am J Nephrol"},{"key":"10.1016\/j.acvd.2020.09.002_bib0920","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.2353\/ajpath.2007.061088","article-title":"Pathology and pathogenesis of severe acute respiratory syndrome","volume":"170","author":"Gu","year":"2007","journal-title":"Am J Pathol"},{"key":"10.1016\/j.acvd.2020.09.002_bib0925","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1001\/jamacardio.2020.1017","article-title":"Cardiovascular Implications of Fatal Outcomes of Patients With Coronavirus Disease 2019 (COVID-19)","volume":"5","author":"Guo","year":"2020","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.acvd.2020.09.002_bib0930","first-page":"507","article-title":"Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan","volume":"395","author":"Chen","year":"2020","journal-title":"China: a descriptive study. Lancet"},{"key":"10.1016\/j.acvd.2020.09.002_bib0935","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1001\/jama.2020.1585","article-title":"Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan","volume":"323","author":"Wang","year":"2020","journal-title":"China. JAMA"},{"key":"10.1016\/j.acvd.2020.09.002_bib0940","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1001\/jamainternmed.2020.0994","article-title":"Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease 2019 Pneumonia in Wuhan","volume":"180","author":"Wu","year":"2020","journal-title":"China. JAMA Intern Med"},{"key":"10.1016\/j.acvd.2020.09.002_bib0945","doi-asserted-by":"crossref","first-page":"7809","DOI":"10.1073\/pnas.0711241105","article-title":"Modulation of TNF-alpha-converting enzyme by the spike protein of SARS-CoV and ACE2 induces TNF-alpha production and facilitates viral entry","volume":"105","author":"Haga","year":"2008","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.acvd.2020.09.002_bib0950","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1007\/s11427-020-1643-8","article-title":"Clinical and biochemical indexes from 2019-nCoV infected patients linked to viral loads and lung injury","volume":"63","author":"Liu","year":"2020","journal-title":"Sci China Life Sci"},{"key":"10.1016\/j.acvd.2020.09.002_bib0955","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.1093\/eurheartj\/ehaa235","article-title":"SARS-CoV2: should inhibitors of the renin-angiotensin system be withdrawn in patients with COVID-19?","volume":"41","author":"Kuster","year":"2020","journal-title":"Eur Heart J"},{"key":"10.1016\/j.acvd.2020.09.002_bib0960","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1111\/j.1365-2362.2009.02153.x","article-title":"SARS-coronavirus modulation of myocardial ACE2 expression and inflammation in patients with SARS","volume":"39","author":"Oudit","year":"2009","journal-title":"Eur J Clin Invest"},{"key":"10.1016\/j.acvd.2020.09.002_bib0965","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1161\/CIRCHEARTFAILURE.108.840124","article-title":"Loss of angiotensin-converting enzyme 2 accelerates maladaptive left ventricular remodeling in response to myocardial infarction","volume":"2","author":"Kassiri","year":"2009","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.acvd.2020.09.002_bib0970","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jchf.2018.06.011","article-title":"Initiation, Continuation, Switching, and Withdrawal of Heart Failure Medical Therapies During Hospitalization","volume":"7","author":"Bhagat","year":"2019","journal-title":"JACC Heart Fail"},{"key":"10.1016\/j.acvd.2020.09.002_bib0975","doi-asserted-by":"crossref","first-page":"e004675","DOI":"10.1161\/JAHA.116.004675","article-title":"Initiation, Continuation, or Withdrawal of Angiotensin-Converting Enzyme Inhibitors\/Angiotensin Receptor Blockers and Outcomes in Patients Hospitalized With Heart Failure With Reduced Ejection Fraction","volume":"6","author":"Gilstrap","year":"2017","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.acvd.2020.09.002_bib0980","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/S0140-6736(18)32484-X","article-title":"Withdrawal of pharmacological treatment for heart failure in patients with recovered dilated cardiomyopathy (TRED-HF): an open-label, pilot, randomised trial","volume":"393","author":"Halliday","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.acvd.2020.09.002_bib0985","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1016\/0735-1097(93)90578-O","article-title":"Clinical consequences of angiotensin-converting enzyme inhibitor withdrawal in chronic heart failure: a double-blind, placebo-controlled study of quinapril. The Quinapril Heart Failure Trial Investigators","volume":"22","author":"Pflugfelder","year":"1993","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.acvd.2020.09.002_bib0990","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1159\/000457946","article-title":"Discontinuation\/Dose Reduction of Angiotensin-Converting Enzyme Inhibitors\/Angiotensin Receptor Blockers during Acute Decompensated Heart Failure in African-American Patients with Reduced Left-Ventricular Ejection Fraction","volume":"137","author":"Kane","year":"2017","journal-title":"Cardiology"},{"key":"10.1016\/j.acvd.2020.09.002_bib0995","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/S0735-1097(97)00183-6","article-title":"Long-term anti-ischemic effects of angiotensin-converting enzyme inhibition in patients after myocardial infarction. The Captopril and Thrombolysis Study (CATS) Investigators","volume":"30","author":"van den Heuvel","year":"1997","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.acvd.2020.09.002_bib1000","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1016\/0002-9149(82)90367-8","article-title":"Hemodynamic and hormonal responses during captopril therapy for heart failure: acute, chronic and withdrawal studies","volume":"49","author":"Nicholls","year":"1982","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.acvd.2020.09.002_bib1005","doi-asserted-by":"crossref","first-page":"189S","DOI":"10.1016\/S0895-7061(99)00105-3","article-title":"Interrupting the renin-angiotensin system: the role of angiotensin-converting enzyme inhibitors and angiotensin II receptor antagonists in the treatment of hypertension","volume":"12","author":"Weber","year":"1999","journal-title":"Am J Hypertens"},{"key":"10.1016\/j.acvd.2020.09.002_bib1010","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1056\/NEJM198706043162301","article-title":"Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS)","volume":"316","year":"1987","journal-title":"N Engl J Med"},{"key":"10.1016\/j.acvd.2020.09.002_bib1015","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1056\/NEJM199108013250501","article-title":"Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure","volume":"325","year":"1991","journal-title":"N Engl J Med"},{"key":"10.1016\/j.acvd.2020.09.002_bib1020","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1056\/NEJM199209033271003","article-title":"Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions","volume":"327","year":"1992","journal-title":"N Engl J Med"},{"key":"10.1016\/j.acvd.2020.09.002_bib1025","doi-asserted-by":"crossref","first-page":"2312","DOI":"10.1161\/01.CIR.100.23.2312","article-title":"Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. ATLAS Study Group","volume":"100","author":"Packer","year":"1999","journal-title":"Circulation"},{"key":"10.1016\/j.acvd.2020.09.002_bib1030","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1056\/NEJM199108013250502","article-title":"A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure","volume":"325","author":"Cohn","year":"1991","journal-title":"N Engl J Med"},{"key":"10.1016\/j.acvd.2020.09.002_bib1035","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1016\/S0140-6736(03)14284-5","article-title":"Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial","volume":"362","author":"Granger","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.acvd.2020.09.002_bib1040","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1016\/S0140-6736(03)14283-3","article-title":"Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial","volume":"362","author":"McMurray","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.acvd.2020.09.002_bib1045","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1056\/NEJMoa010713","article-title":"A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure","volume":"345","author":"Cohn","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.acvd.2020.09.002_bib1050","doi-asserted-by":"crossref","first-page":"2338","DOI":"10.1093\/eurheartj\/ehl250","article-title":"The perindopril in elderly people with chronic heart failure (PEP-CHF) study","volume":"27","author":"Cleland","year":"2006","journal-title":"Eur Heart J"},{"key":"10.1016\/j.acvd.2020.09.002_bib1055","doi-asserted-by":"crossref","first-page":"2456","DOI":"10.1056\/NEJMoa0805450","article-title":"Irbesartan in patients with heart failure and preserved ejection fraction","volume":"359","author":"Massie","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.acvd.2020.09.002_bib1060","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/S0140-6736(03)14285-7","article-title":"Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial","volume":"362","author":"Yusuf","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.acvd.2020.09.002_bib1065","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1016\/S0140-6736(03)14286-9","article-title":"Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study","volume":"362","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.acvd.2020.09.002_bib1070","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1056\/NEJM200001203420301","article-title":"Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients","volume":"342","year":"2000","journal-title":"N Engl J Med"},{"key":"10.1016\/j.acvd.2020.09.002_bib1075","doi-asserted-by":"crossref","first-page":"2058","DOI":"10.1056\/NEJMoa042739","article-title":"Angiotensin-converting-enzyme inhibition in stable coronary artery disease","volume":"351","author":"Braunwald","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.acvd.2020.09.002_bib1080","first-page":"669","article-title":"Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction","volume":"327","author":"Pfeffer","year":"1992","journal-title":"Results of the survival and ventricular enlargement trial. The SAVE Investigators. N Engl J Med"},{"key":"10.1016\/j.acvd.2020.09.002_bib1085","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1016\/S0140-6736(95)90865-X","volume":"345","year":"1995","journal-title":"Lancet"},{"key":"10.1016\/j.acvd.2020.09.002_bib1090","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1056\/NEJM199209033271002","article-title":"Effects of the early administration of enalapril on mortality in patients with acute myocardial infarction. Results of the Cooperative New Scandinavian Enalapril Survival Study II (CONSENSUS II)","volume":"327","author":"Swedberg","year":"1992","journal-title":"N Engl J Med"},{"key":"10.1016\/j.acvd.2020.09.002_bib1095","first-page":"821","article-title":"Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure","volume":"342","year":"1993","journal-title":"Lancet"},{"key":"10.1016\/j.acvd.2020.09.002_bib1100","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1056\/NEJM199512213332503","article-title":"A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. Trandolapril Cardiac Evaluation (TRACE) Study Group","volume":"333","author":"Kober","year":"1995","journal-title":"N Engl J Med"},{"key":"10.1016\/j.acvd.2020.09.002_bib1105","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1001\/archinte.166.6.659","article-title":"Effects of angiotensin-converting enzyme inhibition with perindopril on left ventricular remodeling and clinical outcome: results of the randomized Perindopril and Remodeling in Elderly with Acute Myocardial Infarction (PREAMI) Study","volume":"166","year":"2006","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.acvd.2020.09.002_bib1110","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1056\/NEJMoa032292","article-title":"Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both","volume":"349","author":"Pfeffer","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.acvd.2020.09.002_bib1115","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/S0140-6736(98)05012-0","article-title":"Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial","volume":"353","author":"Hansson","year":"1999","journal-title":"Lancet"},{"key":"10.1016\/j.acvd.2020.09.002_bib1120","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1016\/S0140-6736(99)10327-1","article-title":"Randomised trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity the Swedish Trial in Old Patients with Hypertension-2 study","volume":"354","author":"Hansson","year":"1999","journal-title":"Lancet"},{"key":"10.1016\/j.acvd.2020.09.002_bib1125","doi-asserted-by":"crossref","first-page":"2981","DOI":"10.1001\/jama.288.23.2981","article-title":"Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)","volume":"288","year":"2002","journal-title":"JAMA"},{"key":"10.1016\/j.acvd.2020.09.002_bib1130","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1016\/S0140-6736(02)08090-X","article-title":"Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol","volume":"359","author":"Lindholm","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.acvd.2020.09.002_bib1135","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.2337\/diacare.24.12.2091","article-title":"Reduced cardiovascular morbidity and mortality in hypertensive diabetic patients on first-line therapy with an ACE inhibitor compared with a diuretic\/beta-blocker-based treatment regimen: a subanalysis of the Captopril Prevention Project","volume":"24","author":"Niskanen","year":"2001","journal-title":"Diabetes Care"},{"key":"10.1016\/j.acvd.2020.09.002_bib1140","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/S0140-6736(99)12323-7","article-title":"Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy","volume":"355","year":"2000","journal-title":"Lancet"},{"key":"10.1016\/j.acvd.2020.09.002_bib1145","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1056\/NEJMoa011303","article-title":"Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes","volume":"345","author":"Lewis","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.acvd.2020.09.002_bib1150","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1056\/NEJMoa011161","article-title":"Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy","volume":"345","author":"Brenner","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.acvd.2020.09.002_bib1155","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.1016\/S0140-6736(96)11445-8","article-title":"Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy","volume":"349","year":"1997","journal-title":"Lancet"},{"key":"10.1016\/j.acvd.2020.09.002_bib1160","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1161\/CIR.0000000000000312","article-title":"Further Evolution of the ACC\/AHA Clinical Practice Guideline Recommendation Classification System: A Report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines","volume":"133","author":"Halperin","year":"2016","journal-title":"Circulation"},{"key":"10.1016\/j.acvd.2020.09.002_bib1165","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.jacc.2020.05.040","article-title":"Ramipril in High-Risk Patients With COVID-19","volume":"76","author":"Amat-Santos","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.acvd.2020.09.002_bib1170","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.2337\/dc20-0660","article-title":"Clinical Characteristics and Outcomes of Patients With Diabetes and COVID-19 in Association With Glucose-Lowering Medication","volume":"43","author":"Chen","year":"2020","journal-title":"Diabetes Care"},{"key":"10.1016\/j.acvd.2020.09.002_bib1175","doi-asserted-by":"crossref","DOI":"10.1093\/ajh\/hpaa096","article-title":"Use of RAAS inhibitors and risk of clinical deterioration in COVID-19: results from an Italian cohort of 133 hypertensives","author":"Felice","year":"2020","journal-title":"Am J Hypertens"},{"key":"10.1016\/j.acvd.2020.09.002_bib1180","doi-asserted-by":"crossref","first-page":"2058","DOI":"10.1093\/eurheartj\/ehaa433","article-title":"Association of hypertension and antihypertensive treatment with COVID-19 mortality: a retrospective observational study","volume":"41","author":"Gao","year":"2020","journal-title":"Eur Heart J"},{"key":"10.1016\/j.acvd.2020.09.002_bib1185","doi-asserted-by":"crossref","first-page":"430","DOI":"10.21037\/atm.2020.03.229","article-title":"The effect of RAS blockers on the clinical characteristics of COVID-19 patients with hypertension","volume":"8","author":"Huang","year":"2020","journal-title":"Ann Transl Med"},{"key":"10.1016\/j.acvd.2020.09.002_bib1190","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1161\/HYPERTENSIONAHA.120.15324","article-title":"Age and Multimorbidity Predict Death Among COVID-19 Patients: Results of the SARS-RAS Study of the Italian Society of Hypertension","volume":"76","author":"Iaccarino","year":"2020","journal-title":"Hypertension"},{"key":"10.1016\/j.acvd.2020.09.002_bib1195","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.1093\/eurheartj\/ehaa388","article-title":"Characteristics and outcomes of patients hospitalized for COVID-19 and cardiac disease in Northern Italy","volume":"41","author":"Inciardi","year":"2020","journal-title":"Eur Heart J"},{"key":"10.1016\/j.acvd.2020.09.002_bib1200","article-title":"Association of renin-angiotensin-aldosterone system inhibitors with COVID-19-related outcomes in Korea: a nationwide population-based cohort study","author":"Jung","year":"2020","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.acvd.2020.09.002_bib1205","doi-asserted-by":"crossref","first-page":"2052","DOI":"10.1001\/jama.2020.6775","article-title":"Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the New York City Area","volume":"323","author":"Richardson","year":"2020","journal-title":"JAMA"},{"key":"10.1016\/j.acvd.2020.09.002_bib1210","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1080\/10641963.2020.1783549","article-title":"Is the use of ACE inb\/ARBs associated with higher in-hospital mortality in Covid-19 pneumonia patients?","volume":"42","author":"Selcuk","year":"2020","journal-title":"Clin Exp Hypertens"},{"key":"10.1016\/j.acvd.2020.09.002_bib1215","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1093\/cid\/ciaa492","article-title":"Clinical Impact of Renin-angiotensin System Inhibitors on In-hospital Mortality of Patients With Hypertension Hospitalized for Coronavirus Disease 2019","volume":"71","author":"Tedeschi","year":"2020","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.acvd.2020.09.002_bib1220","doi-asserted-by":"crossref","DOI":"10.1007\/s11684-020-0800-y","article-title":"Use of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers in context of COVID-19 outbreak: a retrospective analysis","author":"Xu","year":"2020","journal-title":"Front Med"}],"container-title":["Archives of Cardiovascular Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1875213620302199?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1875213620302199?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T13:46:44Z","timestamp":1761745604000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1875213620302199"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12]]},"references-count":122,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["S1875213620302199"],"URL":"https:\/\/doi.org\/10.1016\/j.acvd.2020.09.002","relation":{},"ISSN":["1875-2136"],"issn-type":[{"value":"1875-2136","type":"print"}],"subject":[],"published":{"date-parts":[[2020,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Severe acute respiratory syndrome coronavirus 2 and renin-angiotensin system blockers: A review and pooled analysis","name":"articletitle","label":"Article Title"},{"value":"Archives of Cardiovascular Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.acvd.2020.09.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Masson SAS.","name":"copyright","label":"Copyright"}]}}